Valeant to buy orphan drug developer Aton for $318M #ucb #pharma #inc

Posted On Dec 6 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #china #pharma

Posted On Nov 17 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #usv #pharma

Posted On Aug 31 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #what #is #big #pharma

Posted On Aug 20 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #mankind #pharma

Posted On Aug 11 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #pharma #resumes

Posted On Aug 4 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #pharmaceutical #sales

Posted On Feb 8 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #watson #pharma

Posted On Jan 11 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #idm #pharma

Posted On Nov 25 2016 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #elder #pharma

Posted On Nov 16 2016 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …